Extended clopidogrel monotherapy versus DAPT in high-risk patients: the OPT-BIRISK trial

Back

ESC Professional Premium Access

Extended clopidogrel monotherapy versus DAPT in high-risk patients: the OPT-BIRISK trial

Session: HOT LINE 7

Topic: Antiplatelet Drugs

Speaker: Professor Y. Han (Shenyang, CN)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Professor Yaling Han

General Hospital of Northern Theater Command, Shenyang (China)

3 presentations

0 follower

8 more presentations in this session

Discussant review - OPT-BIRISK

Speaker: Professor R. Lopes (Durham, US)

Access

Slides

Video

Panel discussion - OPT-BIRISK

Access

Video

ARAMIS - Anakinra versus Placebo in Acute Myocarditis

Speaker: Professor M. Kerneis (Paris, FR)

Discussant review - ARAMIS

Speaker: Doctor E. Ammirati (Milan, IT)

Access

Slides

Video

Panel discussion - ARAMIS

Access

Access the full session

HOT LINE 7

Speakers: Professor Y. Han, Professor R. Lopes, Professor M. Kerneis, Doctor E. Ammirati

Access

Video

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Extended clopidogrel monotherapy versus DAPT in high-risk patients: the OPT-BIRISK trial

About the speaker

Professor Yaling Han

8 more presentations in this session

Discussant review - OPT-BIRISK

Panel discussion - OPT-BIRISK

ARAMIS - Anakinra versus Placebo in Acute Myocarditis

Discussant review - ARAMIS

Panel discussion - ARAMIS

Access the full session

HOT LINE 7

About the event

ESC Congress 2023

ESC 365 is supported by